Holen Sie sich die Stockscreener-App
47.51
1.90%
-0.92
Handel nachbörslich:
47.56
0.05
+0.11%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$48.43
Offen:
$48.44
24-Stunden-Volumen:
7.34M
Relative Volume:
0.51
Marktkapitalisierung:
$96.69B
Einnahmen:
$47.64B
Nettoeinkommen (Verlust:
$5.42B
KGV:
17.79
EPS:
2.67
Netto-Cashflow:
$13.09B
1W Leistung:
+1.76%
1M Leistung:
+2.50%
6M Leistung:
-19.15%
1J Leistung:
-5.83%
1-Tages-Spanne:
$47.34
$48.46
1-Wochen-Bereich:
$46.85
$49.27
52-Wochen-Spanne:
$44.00
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.51 | 98.56B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
808.11 | 729.58B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
166.22 | 405.32B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
188.52 | 336.11B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.18 | 227.85B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
69.00 | 318.59B | 43.59B | 15.04B | 10.74B | 3.3766 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts? - TradingView
MapLight raises $373M to plot phase 2 journey for would-be rival to BMS' Cobenfy - Fierce Biotech
Should I hold or sell Bristol Myers Squibb Company stock in 2025Rapid market gains - jammulinksnews.com
Goldman Sachs Maintains a Hold on Bristol-Myers Squibb (BMY) - Insider Monkey
Bristol Myers Squibb's Leadership Transition: Strategic Continuity or Execution Risks? - AInvest
Ex-BMS General Counsel Joins Bausch Health Board - Law360
Bristol Myers shuffles its executive ranks with new CMO - BioPharma Dive
Oncology Drugs Market Insights, Competitive Landscape, and Forecast Report 2025-2032 | Immunotherapy Leads Growth in Oncology Market Due to Better Precision and Fewer Side Effects - GlobeNewswire Inc.
Bristol Myers’ Top Doctor Exits in Midst of Search for New Hit Drug - Bloomberg
Bristol Myers (BMY) Appoints New Chief Medical Officer | BMY Stock News - GuruFocus
Bristol Myers Squibb Taps AstraZeneca's Star Executive Who Led 150+ Clinical Studies as New CMO - Stock Titan
What drives Bristol Myers Squibb Company Equity Right stock priceAccelerated wealth expansion - PrintWeekIndia
Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock? - The Globe and Mail
Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000' - Benzinga
How Bristol Myers Squibb uses AI to validate drugs before they’re even in the lab - Pharma Voice
The Bristol Myers Squibb Foundation - Bristol Myers Squibb
Jim Cramer on Bristol-Myers: “Never Seen it This Cheap” - Insider Monkey
Dr Reddy's kicks off India big pharma earnings with narrow profit miss - Reuters
Citi Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail
Bristol-Myers Squibb’s Promising CELMoD Pipeline and Revenue Growth Potential: Analyst Buy Rating - TipRanks
Bristol Myers Squibb Company Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com
Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions - PharmTech
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st
What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional
Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis - Investing.com
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa
FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Jim Cramer Reflected on These 17 Stocks - Insider Monkey
Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative
What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com
BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey
Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters
Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace
Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters
Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):